MorphoSys to Host Q2 2009 Conference Call on July 29, 2009
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publishits first six months' 2009 results on July 29, 2009 at 7:00 a.m. CET.At 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EDT), the Management Boardof MorphoSys AG will host a public conference call to presentMorphoSys's financial results for the first six months of 2009 andprovide further details on the Company's latest developments.Dial-in numbers (listen only):Germany: +49 (0) 69 71049 1462United Kingdom: +44 (0) 1212 604 860USA: +1 (1) 866 347 1957An audio replay and manuscripts of the conference will be availableon www.morphosys.com/conferencecalls in the afternoon of the sameday.For further information please contact: Dr. Claudia Gutjahr-Löser,Head of Corporate Communications & Investor Relations, Tel: +49 (0)89 / 899 27-122, gutjahr-loeser(at)morphosys.com or Mario Brkulj, SeniorManager Corporate Communications & Investor Relations, Tel: +49 (0)89 / 899 27-454, brkulj(at)morphosys.comAbout MorphoSys:MorphoSys is a publicly traded biotechnology company focused on thegeneration of fully human antibodies as a means to discover anddevelop innovative antibody-based drugs against life-threateningdiseases. MorphoSys's goal is to establish HuCAL as the technology ofchoice for antibody generation in research, diagnostics andtherapeutic applications. The Company currently has therapeutic andresearch alliances with the majority of the world's largestpharmaceutical companies including Boehringer Ingelheim, CentocorOrtho Biotech Inc./Johnson & Johnson, Novartis, Pfizer and Roche.Within these partnerships, more than 50 therapeutic antibody programsare ongoing in which MorphoSys participates through exclusive licenseand milestones payments as well as royalties on any end products.Additionally, MorphoSys is active in the antibody research marketthrough its AbD Serotec business unit. The business unit hasoperations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.(Oxford). For further information please visithttp://www.morphosys.com/HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registeredtrademarks of MorphoSys AGThis communication contains certain forward-looking statementsconcerning the MorphoSys group of companies. The forward-lookingstatements contained herein represent the judgment of MorphoSys as ofthe date of this release and involve risks and uncertainties. Shouldactual conditions differ from the Company's assumptions, actualresults and actions may differ from those anticipated. MorphoSys doesnot intend to update any of these forward-looking statements as faras the wording of the relevant press release is concerned.http://hugin.info/130295/R/1330547/314562.pdf --- End of Message ---MorphoSys AGLena-Christ-Str. 48 Martinsried / München GermanyWKN: 663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH All Share, TecDAX, MIDCAP;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 23.07.2009 - 14:00 Uhr
Sprache: Deutsch
News-ID 3915
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 275 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Host Q2 2009 Conference Call on July 29, 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
